A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.

Trial Profile

A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Adapalene/benzoyl peroxide (Primary) ; Adapalene; Benzoyl peroxide
  • Indications Acne vulgaris
  • Focus Registrational; Therapeutic Use
  • Sponsors Galderma
  • Most Recent Events

    • 05 Jul 2016 According to a Galderma Pharma media release, based on this and other trial (700235438) the Japan Ministry of Health, Labor and Welfare has approved Epiduo, a for the treatment of acne vulgaris in Japan.
    • 17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 16 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top